19 results about "Cell Cycle Inhibition" patented technology

This invention is in the area of cell cycle inhibiting compounds for the treatment of disorders involving abnormal cellular proliferation, and include selective CDK2 inhibitors for medical therapy and their pharmaceutically acceptable salts and compositions. The inhibitors are pyrimidine-based N-heterocyclic compounds of formula:

This invention provides a method for constructing a human endometrial organoid aging model, belonging to the field of biological model technology. Based on human endometrial organoids, this invention utilizes hydrogen peroxide (H2O2) stimulation to induce a human endometrial organoid aging model. This human endometrial organoid aging model clearly exhibits multiple cellular aging phenotypes, including slowed organoid growth rate, decreased cell proliferation index (Ki67), enhanced SA-β-gal activity, upregulated expression of cell cycle inhibitors P16 and P21, and significantly upregulated gene expression levels of aging-associated secretory phenotype (SASP) components. It can provide an effective tool for screening anti-aging drugs for women, high-throughput and high-content screening, personalized treatment strategy development, and mechanistic research.

The present invention provides the application of miR-151-5p as a target in the preparation of products for regulating follicular development, which belongs to the field of molecular biotechnology. The present invention provides the application of miR-151-5p in the preparation of reagents for regulating the process of follicular development. The miR-151-5p can inhibit cell proliferation, block the cell cycle, and inhibit the expression of genes related to the proliferation of goat ovarian granulosa cells, but can promote the secretion of steroid hormones in goat ovarian granulosa cells, promote the expression of genes related to steroid hormone secretion, and promote the expression of key proteins for the secretion of steroid hormones in ovarian granulosa cells. The present invention also screened the target gene of the miR-151-5p. PGAM1 The miR-151-5p inhibits the target gene by degrading mRNA PGAM1 Therefore, by regulating the miR-151-5p and / or PGAM1 Regulate to control the development of follicles.

The present invention is in the field of cell cycle inhibiting compounds for the treatment of conditions involving abnormal cell proliferation, and includes selective CDK2 inhibitors and pharmaceutically acceptable salts and compositions thereof for medical treatment.

The invention discloses saRNA for activating AMBRA1 transcription, modified saRNA and application of the saRNA and the modified saRNA. AMBRA1 is used as a target spot, saRNA sequences targeting an AMBRA1 promoter region are designed, 31 saRNA sequences and saRNA modified by the saRNA sequences are obtained through screening, and the saRNA sequences and the saRNA modified by the saRNA sequences can up-regulate the expression level of AMBRA1 in tumor cells so as to regulate the cell cycle and inhibit the proliferation, migration and invasion ability of the tumor cells. The invention further studies the feasibility of the saRNA combined chemotherapeutic drug as a tumor combined treatment scheme, and the combined administration of the saRNA and the chemotherapeutic drug further significantly inhibits the proliferation ability of tumor cells, increases apoptosis, and enhances the sensitivity of the tumor cells to the chemotherapeutic drug, so that the prognosis of tumor patients is expected to be improved; the saRNA or the modified saRNA provided by the invention has an application prospect in the aspects of preparation of anti-tumor drugs and preparation of anti-tumor drug combined therapy.

The present invention pertains to the field of cell cycle inhibitory compounds for treating disorders involving abnormal cell proliferation and encompasses selective CDK2 inhibitors for medical treatment, as well as their pharmaceutically acceptable salts and compositions.

The invention belongs to the technical field of biological medicine and pharmacology, and particularly relates to EGCG-5-HT binary oxidation self-agglutination nanoparticles as well as a preparation method and application of the EGCG-5-HT binary oxidation self-agglutination nanoparticles. The EGCG (epigallocatechin gallate)-5-HT binary oxidation auto-agglutination nanoparticles disclosed by the invention are obtained by carrying out oxidation auto-agglutination on EGCG and 5-HT in an alkaline environment. The total concentration of the EGCG and the 5-HT in the reaction liquid is 1.0 to 3.0 mg / mL. The nanoparticles provided by the invention have an anti-oxidation effect, and can inhibit pyroptosis and regulate and control a cell cycle; an NF-kappa B signal channel is inhibited, and the anti-inflammatory effect is achieved; an MAPK signal channel is activated, and cell apoptosis is inhibited; a PI3K-Akt signal channel is activated, and cell proliferation and mucous membrane repair are promoted. When the compound is applied to preparation of IBD medicines, multi-mechanism synergistic treatment of anti-inflammatory, anti-oxidation and mucous membrane repair of IBD is realized; the invention also provides a preparation method of the nanoparticle, and the preparation method is mild in condition and simple.

Provided include methods, compositions and kits for treating hormone receptor positive (HR+) breast cancer, e.g., estrogen receptor positive (ER+) and progesterone receptor positive (PR+) breast cancer, in a subject. The method can comprise administrating a PI3K inhibitor and a cell cycle inhibitor, such as a PLK1 inhibitor, to the subject in a manner sufficient to inhibit or reduce progression of the cancer.

The present disclosure relates to a drug-containing patch comprising a cyclin inhibitor, a cyclin-dependent kinase (CDK) inhibitor as described herein. The patch includes an impermeable layer that acts as a barrier, for example, to prevent water penetration. When the patch is attached to the skin or mucous membranes, the compound is released to treat and / or prevent precancerous oral conditions, oral cancer, and related diseases.

This invention is in the area of cell cycle inhibiting compounds for the treatment of disorders involving abnormal cellular proliferation, and include selective CDK2 inhibitors for medical therapy and their pharmaceutically acceptable salts and compositions.

This invention relates to the field of biotechnology, and more particularly to the application of the chi-miR-1388-3p gene in the melatonin-mediated regulation of cashmere growth in cashmere goats. This invention discovers a microRNA (chi-miR-1388-3p) associated with the growth cycle of cashmere goat hair follicles, which can regulate the proliferation, cell cycle, or apoptosis of hair papilla cells in cashmere goat skin, thereby regulating cashmere goat hair follicle growth and cashmere growth. Furthermore, this invention is the first to discover that melatonin-mediated interference with chi-miR-1388-3p promotes the proliferation of hair papilla cells in cashmere goat skin, regulates the cell cycle, and inhibits apoptosis, providing valuable insights into the regulatory role of melatonin-mediated miRNAs in cashmere goat hair follicle growth.

The invention provides application of miR-151-5p as a target spot in preparation of a product for regulating follicle development, and belongs to the technical field of molecular biology. The invention provides an application of miR-151-5p in preparation of a reagent for regulating a follicle development process, and the miR-151-5p can inhibit cell proliferation, prevent a cell cycle, inhibit expression of goat ovarian granular cell proliferation related genes, inhibit ovarian granular cell proliferation related genes, inhibit ovarian granular cell proliferation related genes and inhibit ovarian granular cell proliferation related genes. But can promote secretion of goat ovarian granular cell steroid hormones, expression of related genes secreted by the steroid hormones, expression of key proteins secreted by the ovarian granular cell steroid hormones, and the like. According to the invention, a target gene PGAM1 of the miR-151-5p is also screened, and the miR-151-5p inhibits the target gene PGAM1 from playing a role in a mode of degrading mRNA (messenger ribonucleic acid). Therefore, the development process of the follicles can be regulated and controlled by regulating and controlling the miR-151-5p and / or the PGAM1.

The invention belongs to the technical field of biological medicine and molecular biology, and particularly relates to application of RNF20 in diagnosis and treatment of diffuse large B-cell lymphoma. Specifically, the RNF20 is remarkably and highly expressed in DLBCL cell lines and tissues, and the high expression of the RNF20 is closely related to poor prognosis of a patient; the RNF20 can play a tumor promoting role by promoting DLBCL cell proliferation, regulating and controlling a cell cycle, inhibiting cell apoptosis and positively regulating and controlling FUS protein expression, and the drug sensitivity of DLBCL cells to ibrutinib can be enhanced by knocking down the RNF20. In a word, the research result shows that the RNF20 can serve as a treatment target, a new thought and a new direction are provided for DLBCL prognosis evaluation and targeted therapy, and therefore the RNF20 has good practical application value.

The application discloses a kind of nitrogen-containing heterocyclic compounds, preparation method and purposes, specifically, a kind of nitrogen-containing heterocyclic compounds as shown in general formula I, or its pharmaceutically acceptable salt, or its enantiomer, diastereoisomer, tautomer, torsion isomer, solvate, polymorph or prodrug, its preparation method and pharmaceutical application, wherein the definition of each group is described in the specification.

The invention provides a construction method of a human endometrial organ aging model, and belongs to the technical field of biological models. On the basis of a human endometrial organ, hydrogen peroxide (H2O2) is utilized to stimulate and induce to obtain the human endometrial organ aging model. The human endometrial organoid senescence model can clearly present various cell senescence phenotypes such as slow down of organoid growth speed, reduction of cell proliferation index (Ki67), enhancement of SA-beta-gal activity, up-regulation of expression of cell cycle inhibition proteins P16 and P21, significant up-regulation of gene expression level of senescence-related secretion phenotype (SASP) components, and the like. And an effective tool can be provided for female anti-aging drug screening, high-throughput and high-content screening, individualized treatment strategy development and mechanism research.

Provided herein are compositions and methods of treating cancer with combinations of cell cycle inhibitors and LSD1 inhibitors. In some aspects, the cell cycle inhibitor is a CDK4 / 6 inhibitor, e.g., palbociclib. In some aspects, the LSD1 inhibitor is MC2580 or DDP38003. The compositions and methods of the disclosure may be used to treat cancers including, but not limited to, leukemia, lung cancer, melanoma, or breast cancer. The cancers may be, for example, LSD1-inhibitor-resistant and / or comprise cells having a reduced level of p21 expression or a loss of p21 function.

Provided is a method for treating cancer by combining an alkylating agent prodrug and a cell cycle inhibitor. The alkylating agent prodrug may be a prodrug of an AKR1C3 enzyme-activated alkylating agent or a prodrug of a hypoxia-activated alkylating agent. The cell cycle inhibitor may be a CDK inhibitor, a WEE inhibitor, a CHK inhibitor, or an ATR inhibitor.

The application discloses genetically engineered diatoms and a construction method and application thereof, and the diatoms have two phenotypes: (1) the diatoms are expanded in a single layer two-dimensional plane on a solid or semi-solid substrate, and cell vertical stacking index is less than or equal to 0.2; and (2) after the projection area of a colony population reaches a preset threshold, cell division and migration behavior are autonomously stopped, and the final colony diameter deviates from the preset value by less than or equal to 15%. The SIN1 gene and the ARPC3 gene in the diatom genome are simultaneously knocked out by using a CRISPR / Cas9 system; and a planar polarity maintenance gene (such as Polar1 of Tetrahymena thermophila) is expressed in a heterologous manner, so that the diatoms are changed from three-dimensional stacking growth to controllable single-layer plane expansion. A synthetic size sensing-termination loop is introduced: the expression of a cell cycle inhibitor is driven by using a promoter sensitive to the projection area of the cell. The digital size programming of the colony growth of the diatoms is realized for the first time, and has a significant industrial application prospect.